Intelligence · Clinical Pipeline

AbbVie Deutschland GmbH Pipeline

All ClinicalTrials.gov programs at AbbVie Deutschland GmbH — phase, modality, and trial IDs.

Programs: 20

Quick answer

AbbVie Deutschland GmbH has 20 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications

AbbVie Deutschland GmbH & Co. KG

locally advanced or metastatic solid tumors

phase 1 other active

1 trial
A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 as monotherapy and in combination with bevacizumab in adult subjects with advanced solid tumors

AbbVie Deutschland GmbH & Co. KG

Advanced solid tumors including (but not limited to), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), gastric/gastroesophageal junction adenocarcinoma (GEA), colorectal cancer (CRC), and renal cell carcinoma (RCC)

phase 1 other active

1 trial
A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors.

AbbVie Deutschland GmbH & Co. KG

Advanced solid tumors

phase 1 other active

1 trial
A Phase 1b, Open-Label Study of Eftozanermin Alfa (ABBV-621) in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

AbbVie Deutschland GmbH & Co. KG

Multiple Myeloma

phase 1 other active

1 trial
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

AbbVie Deutschland GmbH & Co. KG

Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia

phase 1 other active

1 trial
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

AbbVie Deutschland GmbH & Co. KG

Myelodysplastic Syndromes (MDS)

phase 1 other active

1 trial
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Compared to Oral Lenvatinib Capsules in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

AbbVie Deutschland GmbH & Co. KG

Squamous-Cell Non-Small Cell Lung Cancer, Hepatocellular Cancer

phase 1 other active

1 trial
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

AbbVie Deutschland GmbH & Co. KG

Relapsed/Refractory Multiple Myeloma

phase 1 other active

1 trial
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants with Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)

AbbVie Deutschland GmbH & Co. KG

Systemic Lupus Erythematosus, Sjogren's disease

phase 1 other active

1 trial
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

AbbVie Deutschland GmbH & Co. KG

Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer

phase 1 other active

1 trial
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

AbbVie Deutschland GmbH & Co. KG

Follicular lymphoma (FL), Chronic lymphocytic leukemia (CLL), Diffuse large b-cell lymphoma (DLBCL), B-cell malignancies

phase 1 other active

1 trial
A Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors

AbbVie Deutschland GmbH & Co. KG

Patients with relapsed or refractory solid tumors, including: Small cell lung cancer (SCLC); Non-small cell cancer (NSCLC); Breast cancer

phase 1 other active

1 trial
A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of Etentamig (ABBV-383) in patients with relapsed or refractory Multiple Myeloma

AbbVie Deutschland GmbH & Co. KG

Relapsed or Refractory Multiple Myeloma (R/R MM)

phase 1 other active

1 trial
Jakavi 10 mg tablets, CELECOXIB , Navitoclax, Navitoclax, Jakavi 10 mg tablets, Jakavi 5 mg tablets, Jakavi 5 mg tablets, Jakavi 5 mg tablets, Jakavi 10 mg tablets

AbbVie Deutschland GmbH & Co. KG

Myelofibrosis, Myeloproliferative Neoplasms

phase 1 small molecule active

1 trial
Livmoniplimab, Budigalimab

AbbVie Deutschland GmbH & Co. KG

Locally Advanced or Metastatic Solid Tumors, Solid Tumors

phase 1 small molecule active

1 trial
Mass Balance Study of [14C] ABBV-932 in Healthy Male Volunteers

AbbVie Deutschland GmbH & Co. KG

Healthy Volunteers

phase 1 other active

1 trial
PIVEKIMAB SUNIRINE

AbbVie Deutschland GmbH & Co. KG

Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloid Leukemia, Acute Myeloid Leukemia

phase 1 small molecule active

1 trial
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

AbbVie Deutschland GmbH & Co. KG

Non-Hodgkin's Lymphoma

phase 1 other active

1 trial
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

AbbVie Deutschland GmbH & Co. KG

Select B-Cell malignancies.

phase 1 other active

1 trial
Study to evaluate the safety, tolerability, maximum tolerated dose and clinical activity of TNB-383B when given to patients with multiple myeloma

AbbVie Deutschland GmbH & Co. KG

Relapsed or refractory multiple myeloma

phase 1 other active

1 trial

Frequently asked questions

How many pipeline programs does AbbVie Deutschland GmbH have?

20 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Quick answer

A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications

A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 as monotherapy and in combination with bevacizumab in adult subjects with advanced solid tumors

A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors.

A Phase 1b, Open-Label Study of Eftozanermin Alfa (ABBV-621) in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Compared to Oral Lenvatinib Capsules in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants with Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

A Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors

A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of Etentamig (ABBV-383) in patients with relapsed or refractory Multiple Myeloma

Jakavi 10 mg tablets, CELECOXIB , Navitoclax, Navitoclax, Jakavi 10 mg tablets, Jakavi 5 mg tablets, Jakavi 5 mg tablets, Jakavi 5 mg tablets, Jakavi 10 mg tablets

Livmoniplimab, Budigalimab

Mass Balance Study of [14C] ABBV-932 in Healthy Male Volunteers

PIVEKIMAB SUNIRINE

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Study to evaluate the safety, tolerability, maximum tolerated dose and clinical activity of TNB-383B when given to patients with multiple myeloma

Frequently asked questions

Stay Ahead in Pharma